AVXL Historical PE Ratio Notes

— Anavex Life Sciences (AVXL) is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurodegenerative and neurodevelopmental disorders, primarily Alzheimer’s disease, Rett syndrome & Parkinson’s disease dementia. Its core pipeline centers on ANAVEX®2-73 (blarcamesine), a proprietary small-molecule drug designed to modulate the sigma-1 receptor for potential disease-modifying effects. AVXL’s revenue sources are currently minimal, as its drug candidates are still in development and not yet commercialized, which significantly impacts its historical earnings. When you examine historical price, earnings, & pe ratio data for AVXL, you’ll likely notice a high or undefined pe ratio for most periods—this is typical for clinical-stage biotech firms before product approval & sales ramp-up. Earnings for such companies are often negative or near-zero, causing the pe ratio to be either extremely high or not meaningful. Investors typically value AVXL on future growth expectations and clinical progress rather than current profit, so movements in the pe ratio often reflect changing market sentiment about the likelihood of drug trial successes, regulatory milestones, and long-term commercial potential rather than conventional earnings performance.

On this page we presented the AVXL Historical PE Ratio information for Anavex Life Sciences' stock. The average AVXL historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 11.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average AVXL historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this AVXL historical PE result, against the recent PE: when this page was posted on 8/28/2026, the most recent closing price for AVXL had been 2.99, and the most recent quarterly earnings result, annualized, was 0.32. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent AVXL PE on 8/28/2026 based on annualized quarterly EPS was 9.3. Based on AVXL's history, that recent PE is low relative to the historical average, with the recent PE 16.2% lower than the historical average PE across our data set for Anavex Life Sciences.

For self directed investors doing their due diligence on AVXL or any other given stock, valuation analysis for AVXL can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Anavex Life Sciences PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for AVXL. Thanks for visiting, and the next time you need to research AVXL Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.